Clinical Trials Related to Vertex Pharmaceuticals Incorporated

Related studies linked through entity extraction aliases.

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Status: COMPLETED
Phase: PHASE3

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Status: COMPLETED
Phase: PHASE3

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Status: COMPLETED
Phase: PHASE3

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Status: COMPLETED
Phase: PHASE3

Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)

Status: COMPLETED
Phase: PHASE2

Energy Balance and Weight Gain With Ivacaftor Treatment

Status: COMPLETED
Phase: N/A

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

Status: COMPLETED
Phase: PHASE2

An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor

Status: COMPLETED
Phase: PHASE1

Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1

Status: COMPLETED
Phase: PHASE2

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Status: COMPLETED
Phase: PHASE3

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Status: COMPLETED
Phase: PHASE3

Phase 1, QT/QTC Interval Study in Healthy Subjects

Status: COMPLETED
Phase: PHASE1

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Status: COMPLETED
Phase: PHASE1

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Status: COMPLETED
Phase: PHASE3

Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

Status: WITHDRAWN
Phase: PHASE2/PHASE3

Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects

Status: COMPLETED
Phase: PHASE1

Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects

Status: COMPLETED
Phase: PHASE1

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Status: COMPLETED
Phase: N/A

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Status: COMPLETED
Phase: PHASE2

A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

Status: COMPLETED
Phase: PHASE2/PHASE3